NITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: UEMURA et al. 7)

Application No.: 09/856,371

Filed: May 21, 2001

For: NOVEL SERINE PROTEASE BSSP2

Art Unit: 1652

Examiner: Y. D. Pak

Washington, D.C.

Atty.'s Docket: UEMURA7

Date: November 19, 2004

OR

OR

THE HONORABLE COMMISSIONER FOR PATENTS U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop: Amendment Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

Sir:

Transmitted herewith is a [X] Amendment [] in the above-identified application.

Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS	
TOTAL	* 4	MINUS	** 30	0	
INDEP.	* 1	MINUS	*** 3	0	
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					

	SMALL ENTITY				
		RATE	ADDITIONAL FEE		
	х	9	\$		
	х	44	\$		
	+	150	\$		
ADDITIONAL FEE TOTAL			\$		

CHALL ENTITY

OTHER THAN SMALL ENTITY ADDITIONAL RATE FEE 18 88 \$ 300 \$ **TOTAL** \$

If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity	С	othe	er Th	an Small	Enti	ity		
Response Filed Within	R	tes	pons	e Filed W	'ithir	1		
[] First - \$ 55.00	[}		First	-	\$	110.00)
[] Second - \$ 215.00	1]		Second	-	\$	430.00)
[] Third - \$ 490.00	[]		Third	-	\$	980.00)
[] Fourth - \$ 765.00	[]		Fourth	-	\$	1530.00)
Month After Time Period Set	M	1on	th Af	ter Time	Peri	od :	Set	
[] Less fees (\$) already paid for month(s) extension of time of the second s	-		· ·					
Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the	ne amo	oun	nt of \$	S				
A check in the amount of \$ is attached (check no.).								
The Commissioner is hereby outherized and requested to charge any addition	aal fac		. doinh	mayba		iiro	d in ann	

The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

Registration No.: 37,971

Facsimile: Telephone: (202) 737-3528 (202) 628-5197



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	ATTY.'S	DOCKET: UEMURA=7
In re Application of:)	Art Unit: 1652
H. UEMURA et al.))	Examiner: Y. D. Pak
Appln. No.: 09/856,371)	Washington, D.C.
Filed: May 21, 2001)	Confirmation No.: 8300
For: NOVEL SERINE PROTEASE BSSP2))	November 19, 2004

AMENDMENT

Honorable Commissioner for Patents U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop Amendment Crystal Plaza Two, Lobby, Room 1803 Arlington, Virginia 22202

Sir:

In response to the Office Action of October 1, 2004, please amend as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.